|Bid||6.71 x 800|
|Ask||6.72 x 900|
|Day's Range||6.71 - 7.02|
|52 Week Range||5.36 - 17.83|
|Beta (3Y Monthly)||0.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.14|
Roger Tung has been the CEO of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) since 2006. First, this article will...
Concert (CNCE) delivered earnings and revenue surprises of 15.29% and -97.14%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Concert Pharmaceuticals, Inc. (CNCE) today announced that it will host a conference call and webcast event with a key opinion leader in the field of psychiatry and schizophrenia on Thursday, November 14, 2019. The event will highlight CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schizophrenia. The Company intends to advance CTP-692 into Phase 2 clinical evaluation in the fourth quarter of 2019.
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. […]
Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Concert Pharmaceuticals, Inc. (CNCE) today announced that it will report its third quarter 2019 financial results on Thursday, November 7, 2019, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss third quarter financial results and provide a business update. A live webcast of the conference call may be accessed in the Investors section of the Company’s website at www.concertpharma.com.
Concert Pharmaceuticals, Inc. (CNCE) today presented results from its recently completed Phase 2 dose-ranging trial of the investigational medicine CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss. Patients in the study treated with either 8 mg twice-daily or 12 mg twice-daily of CTP-543 met the primary efficacy endpoint with statistically significant differences (p
Concert Pharmaceuticals, Inc. (CNCE) today announced that it will be providing an overview of the Company’s clinical pipeline following recent updates on the AVP-786 partnered program in a presentation at the Cantor Healthcare Conference on Thursday, October 3, 2019 at 5:20 p.m. ET in New York, NY. “While we’re disappointed by the recent results generated by our collaborators in the AVP-786 Phase 3 Alzheimer’s agitation trial, we are highly focused on the distinct value of Concert’s proprietary drug candidates, CTP-543 for alopecia areata and CTP-692 for schizophrenia,” stated Roger Tung, Ph.D., President and CEO of Concert Pharmaceuticals.
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you...
If you're interested in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE), then you might want to consider its beta (a...
Concert (CNCE) delivered earnings and revenue surprises of 15.22% and -83.67%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
Concert Pharma (CNCE) reports favorable data from the two early-stage studies on its pipeline candidate, CTP-692, currently under evaluation as an adjunctive treatment for schizophrenia. Share rise.
Concert Pharmaceuticals, Inc. (CNCE) today reported positive results from two studies in its Phase 1 program evaluating CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schizophrenia. Despite evidence of benefit in multiple published clinical studies of non-deuterated D-serine in the treatment of schizophrenia, its use has been limited due to renal safety concerns. Furthermore, in contrast to non-deuterated D-serine, which has been reported to display highly variable pharmacokinetic behavior in humans, CTP-692 was found to have low inter-individual pharmacokinetic variability.